BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 . Bibliography. Current world literature. Outcome measures. Curr Opin Allergy Clin Immunol 2006;6:241-4. [PMID: 16670521 DOI: 10.1097/01.all.0000225167.72842.fd] [Reference Citation Analysis]
2 Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719-730. [PMID: 26193978 DOI: 10.1111/apt.13325] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 20.9] [Reference Citation Analysis]
3 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
4 Pontes P, Tiago R. Diagnosis and management of laryngopharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14:138-142. [PMID: 16728889 DOI: 10.1097/01.moo.0000193193.09602.51] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
5 Liu ZZ, Ren Q, Zhou YN, Yang HM. Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects. World J Clin Cases 2020; 8(22): 5518-5528 [PMID: 33344542 DOI: 10.12998/wjcc.v8.i22.5518] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kim DK, Lee K, Kim S, Kim S, Lee SJ, Park CH, Kim B, Song G, Moon B, Ryu S. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid–Related Disease. J Pharmacol Exp Ther 2019;369:318-27. [DOI: 10.1124/jpet.118.254904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Zhou Y, Wang J, Gu Z, Wang S, Zhu W, Aceña JL, Soloshonok VA, Izawa K, Liu H. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chem Rev 2016;116:422-518. [PMID: 26756377 DOI: 10.1021/acs.chemrev.5b00392] [Cited by in Crossref: 1271] [Cited by in F6Publishing: 887] [Article Influence: 211.8] [Reference Citation Analysis]
8 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
9 Sharma VD, Akocak S, Ilies MA, Fassihi R. Solid-state interactions at the core-coat interface: physicochemical characterization of enteric-coated omeprazole pellets without a protective sub-coat. AAPS PharmSciTech 2015;16:934-43. [PMID: 25595125 DOI: 10.1208/s12249-014-0263-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
10 Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
11 Lin K, Chen X, Zhang L, Wang Y, Shan Z. Proton pump inhibitors as also inhibitors of atrial fibrillation. Eur J Pharmacol 2013;718:435-40. [PMID: 23973848 DOI: 10.1016/j.ejphar.2013.07.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
12 Lou H, Yuan H, Ruan Z, Xu D, Zhou Q. LC Determination and Bioequivalence Study of Pantoprazole in Human Plasma. Chroma 2008;67:795-9. [DOI: 10.1365/s10337-008-0563-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Huang ST, Tseng LY, Chen LK, Peng LN, Hsiao FY. Does Long-Term Proton Pump Inhibitor Use Increase Risk of Dementia? Not Really! Results of the Group-Based Trajectory Analysis. Clin Pharmacol Ther 2019;106:616-22. [PMID: 30861103 DOI: 10.1002/cpt.1430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Nishida H, Arikawa Y, Hirase K, Imaeda T, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Hamada T, Iida M, Nishitani M, Imanishi A, Fukui H, Itoh F, Kajino M. Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action. Bioorganic & Medicinal Chemistry 2017;25:3298-314. [DOI: 10.1016/j.bmc.2017.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
15 Lim SL, Goh WT, Lee JM, Ng TP, Ho KY. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol. 2005;20:995-1001. [PMID: 15955205 DOI: 10.1111/j.1440-1746.2005.04167.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
16 Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals. J Pharmacol Exp Ther 2011;337:797-804. [DOI: 10.1124/jpet.111.179556] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
17 Freitas CS, Baggio CH, Finau J, Anginoni M, Pizzolatti MG, Santos ARS, Marques MCA. Inhibition of H+/K+ ATPase in the gastroprotective effect of Baccharis illinita DC. Journal of Pharmacy and Pharmacology 2008;60:1105-10. [DOI: 10.1211/jpp.60.8.0017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
18 Bladh N, Blychert E, Johansson K, Backlund A, Lundin C, Niazi M, Pettersson G, Fjellman M. A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. Clin Ther. 2007;29:640-649. [PMID: 17617287 DOI: 10.1016/j.clinthera.2007.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
19 Kirchhoff P, Socrates T, Sidani S, Duffy A, Breidthardt T, Grob C, Viehl CT, Beglinger C, Oertli D, Geibel JP. Zinc salts provide a novel, prolonged and rapid inhibition of gastric acid secretion. Am J Gastroenterol. 2011;106:62-70. [PMID: 20736941 DOI: 10.1038/ajg.2010.327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Guan J, Li H, Yan F, Shi S, Wang S. Optimization and validation of a novel CE method for the enantioseparation of pantoprazole and related benzimididazole using a dual chiral selector system: CE and CEC. ELECTROPHORESIS 2014;35:2800-6. [DOI: 10.1002/elps.201400305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
21 Untersmayr E. Acid suppression therapy and allergic reactions. Allergo J Int 2015;24:303-11. [PMID: 28603686 DOI: 10.1007/s40629-015-0085-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
22 Kirchhoff P, Andersson K, Socrates T, Sidani S, Kosiek O, Geibel JP. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2006;291:G838-43. [PMID: 16798725 DOI: 10.1152/ajpgi.00120.2006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
23 Maróstica M, Arçari DP, Bartchewsky W, Trevisan M, Ribeiro ML, Pedrazzoli J, Hoehr NF, Gambero A. Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori -infected mice. Scandinavian Journal of Gastroenterology 2009;42:1404-12. [DOI: 10.1080/00365520701514396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, Kearney KR, Rudolph D, Thornton JJ. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14:647-660. [PMID: 19443264 DOI: 10.1016/j.drudis.2009.03.014] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
25 Fornai M, Colucci R, Antonioli L, Ghisu N, Tuccori M, Blandizzi C, Del Tacca M. Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. Naunyn Schmiedebergs Arch Pharmacol 2009;379:305-13. [PMID: 18853145 DOI: 10.1007/s00210-008-0355-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Nantavishit J, Chatsudthipong V, Soodvilai S. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion. Biochemical Pharmacology 2018;154:175-82. [DOI: 10.1016/j.bcp.2018.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6:29-41. [PMID: 19968574 DOI: 10.1517/17425250903386251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
28 Guan J, Yang J, Li J, Li X, Li F. Determination of tenatoprazole enantiomers and their enantioselective pharmacokinetics in rats. Chirality. 2009;21:613-618. [PMID: 18752288 DOI: 10.1002/chir.20657] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
29 Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Biochem Pharmacol 2006;71:837-49. [PMID: 16405921 DOI: 10.1016/j.bcp.2005.11.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
30 Fang H, Jin L, Huang N, Wang J, Zou K, Luo Z. Synthesis, Structure and H + /K + -ATPase Inhibitory Activity of Novel Triazolyl Substituted Tetrahydrobenzofuran Derivatives via One-pot Three-component Click Reaction. Chin J Chem 2013;31:831-6. [DOI: 10.1002/cjoc.201300119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G. Quantification of tenatoprazole in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr 2007;21:1240-4. [DOI: 10.1002/bmc.875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Liu F, Shou C, Geng Q, Zhao C, Xu J, Yu H. A Baeyer-Villiger monooxygenase from Cupriavidus basilensis catalyzes asymmetric synthesis of (R)-lansoprazole and other pharmaco-sulfoxides. Appl Microbiol Biotechnol 2021;105:3169-80. [PMID: 33779786 DOI: 10.1007/s00253-021-11230-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chen ZY, Xie HT, Zheng QS, Sun RY, Hu G. Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. Eur J Drug Metab Pharmacokinet 2006;31:27-33. [PMID: 16715780 DOI: 10.1007/BF03190639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446-4456. [PMID: 22512618 DOI: 10.1021/jm300318t] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
35 Weiss C, Rubach M, Lang R, Seebach E, Blumberg S, Frank O, Hofmann T, Somoza V. Measurement of the Intracellular pH in Human Stomach Cells: A Novel Approach To Evaluate the Gastric Acid Secretory Potential of Coffee Beverages. J Agric Food Chem 2010;58:1976-85. [DOI: 10.1021/jf903614d] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
36 Ma C, Wu A, Wu Y, Ren X, Cheng M. Design and Synthesis of N -Aryl Isothioureas as a Novel Class of Gastric H + /K + -ATPase Inhibitors: N -Aryl Isothioureas as Gastric H + /K + -ATPase Inhibitors. Arch Pharm Chem Life Sci 2013;346:891-900. [DOI: 10.1002/ardp.201300276] [Cited by in Crossref: 8] [Article Influence: 0.9] [Reference Citation Analysis]
37 Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231-238. [PMID: 20624992 DOI: 10.1124/jpet.110.170274] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 10.4] [Reference Citation Analysis]
38 Schuler A. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. Geriatr Nurs 2007;28:225-9. [PMID: 17936957 DOI: 10.1016/j.gerinurse.2007.06.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Paresi CJ, Liu Q, Li YM. Benzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free setting. Mol Biosyst 2016;12:1772-80. [PMID: 26952080 DOI: 10.1039/c6mb00024j] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
40 Guan J, Li J, Yan F, Gu H, Li F. Chiral Separation of Tenatoprazole and Several Related Benzimidazoles by Normal Phase LC Using Amylose-Based Stationary Phase. Chroma 2009;70:1039-44. [DOI: 10.1365/s10337-009-1296-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Sripathi S, Bojja RR, Karnati VR, Raju VVNKVP, Khunt MD. An Improved Synthesis of Antiulcerative Drug: Tenatoprazole. Org Process Res Dev 2009;13:804-6. [DOI: 10.1021/op800173u] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
42 Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen 2012;17:177-82. [PMID: 21940711 DOI: 10.1177/1087057111421004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
43 Song W, Zhou Y, Fu Y, Xu W. Self-disproportionation of enantiomers of prazoles via achiral, gravity-driven silica gel column chromatography. Tetrahedron: Asymmetry 2013;24:909-12. [DOI: 10.1016/j.tetasy.2013.06.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
44 Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, Shibakawa N. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther. 2007;323:308-317. [PMID: 17630360 DOI: 10.1124/jpet.107.121350] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
45 Untersmayr E, Jensen-Jarolim E. The effect of gastric digestion on food allergy. Curr Opin Allergy Clin Immunol. 2006;6:214-219. [PMID: 16670517 DOI: 10.1097/01.all.0000225163.06016.93] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
46 Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189-193. [PMID: 17066244 DOI: 10.1007/s11096-006-9028-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
47 Ohkuma K, Iida H, Inoh Y, Kanoshima K, Ohkubo H, Nonaka T, Fujita K, Kusakabe A, Inamori M, Nakajima A. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr 2018;63:80-3. [PMID: 30087548 DOI: 10.3164/jcbn.17-128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
48 Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006;38:415-428. [PMID: 17008305 DOI: 10.1080/07853890600925843] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
49 Ito K, Kinoshita K, Tomizawa A, Morikawa-inomata Y, Inaba F, Fujita Y, Tabata K, Shibakawa N. The Effect of Subchronic Administration of 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1 S ,2 S )-2-methylcyclopropyl]methyl}-1 H -pyrrolo[2,3- d ]pyridazine (CS-526), a Novel Acid Pump Antagonist, on Gastric Acid Secretion and Gastrin Levels in Rats. J Pharmacol Exp Ther 2008;326:163-70. [DOI: 10.1124/jpet.108.137299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]